Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 95, Issue 3, 2010, Pages 1404-1411

  Weigert, Johanna ^a   Neumeier, Markus ^a   Wanninger, Josef ^a   Bauer, Sabrina ^a   Farkas, Stefan ^a   Scherer, Marcus N ^a   Schnitzbauer, Andreas ^a   Schäffler, Andreas ^a   Aslanidis, Charalampos ^a   Schölmerich, Jürgen ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; GLYCOSYLATED HEMOGLOBIN; INSULIN; INTERLEUKIN 6; LEPTIN; METFORMIN; RESISTIN; SULFONYLUREA;

ADIPOCYTE; ADIPOSE TISSUE; ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATIC VEIN; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CIRRHOSIS; MALE; MEASUREMENT; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PORTAL VEIN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SERUM;

RODENTIA;

EID: 77749239761     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2009-1619     Document Type: Article

References (44)

1. Zeyda M, Farmer D, Todoric J, Aszmann O, Speiser M, Gyori G, Zlabinger GJ, Stulnig TM 2007 Human adipose tissue macrophages are of an anti-inflammatory phenotype but capable of excessive pro-inflammatory mediator production. Int J Obes (Lond) 31:1420-1428
2. Bays HE 2009 "Sick fat," metabolic disease, and atherosclerosis. Am J Med 122:S26-S37
3. Berg AH, Scherer PE 2005 Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96:939-949
4. Rabe K, Lehrke M, Parhofer KG, Broedl UC 2008 Adipokines and insulin resistance. Mol Med 14:741-751
5. Rasouli N, Kern PA 2008 Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 93:S64-S73
6. Boden G 2008 Obesity and free fatty acids. Endocrinol Metab Clin North Am 37:635-646, viii-ix
7. Despres JP, Arsenault BJ, Cote M, Cartier A, Lemieux I 2008 Abdominal obesity: the cholesterol of the 21st century? Can J Cardiol 24(Suppl D):7D-12D
8. Demerath EW, Reed D, Rogers N, Sun SS, Lee M, Choh AC, Couch W, Czerwinski SA, Chumlea WC, Siervogel RM, Towne B 2008 Visceral adiposity and its anatomical distribution as predictors of the metabolic syndrome and cardiometabolic risk factor levels. Am J Clin Nutr 88:1263-1271
9. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, Olivieri A, Sorcini M, Di Mario U, Pesce C, Pugliese G 2004 Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as anAGE receptor. FASEB J 18:1773-1775
10. Kiwaki K, Novak CM, Hsu DK, Liu FT, Levine JA 2007 Galectin-3 stimulates preadipocyte proliferation and is up-regulated in growing adipose tissue. Obesity (Silver Spring) 15:32-39
11. Dumic J, Dabelic S, Flögel M 2006 Galectin-3: an open-ended story. Biochim Biophys Acta 1760:616-635
12. Hsu DK, Dowling CA, Jeng KC, Chen JT, Yang RY, Liu FT 1999 Galectin-3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int J Cancer 81:519-526
13. Iacovazzi PA, Notarnicola M, Caruso MG, Guerra V, Frisullo S, Altomare DF, Correale M 18 August 2009 Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients. Immunopharmacol Immunotoxicol 10.1080/08923970902936880
14. Henderson NC, Sethi T 2009 The regulation of inflammation by galectin-3. Immunol Rev 230:160-171
15. Weber M, Sporrer D, Weigert J, Wanninger J, Neumeier M, Wurm S, Stögbauer F, Kopp A, Bala M, Schäffler A, Buechler C 2009 Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes. FEBS Lett 583:3718-3724
16. Nachtigal M, Al-Assaad Z, Mayer EP, Kim K, Monsigny M 1998 Galectin-3 expression in human atherosclerotic lesions.AmJ Pathol 152:1199-1208
17. Nachtigal M, Ghaffar A, Mayer EP 2008 Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 172:247-255
18. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, Liu FT, Lukic ML 2009 Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol 130: 83-88
19. Beisswenger PJ, Szwergold BS, Yeo KT 2001 Glycated proteins in diabetes. Clin Lab Med 21:53-78, vi
20. Rahbar S 2005 The discovery of glycated hemoglobin: a major event in the study of nonenzymatic chemistry in biological systems. Ann NY Acad Sci 1043:9-19
21. Nomoto K, Tsuneyama K, Abdel Aziz HO, Takahashi H, Murai Y, Cui ZG, Fujimoto M, Kato I, Hiraga K, Hsu DK, Liu FT, Takano Y 2006 Disrupted galectin-3 causes non-alcoholic fatty liver disease in male mice. J Pathol 210:469-477
22. Fontana L, Eagon JC, Trujillo ME, Scherer PE, Klein S 2007 Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 56:1010-1013
23. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, Farkas S, Scherer MN, Schaffler A, Aslanidis C, Scholmerich J, Buechler C 24 June 2009 Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 10.1111/j.1365-2265.2009.03664.x
24. Hajer GR, van Haeften TW, Visseren FL 2008 Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 29:2959-2971
25. Meyers JA, Liu AY, McTiernan A, Wener MH, Wood B, Weigle DS, Sorensen B, Chen-Levy Z, Yasui Y, Boynton A, Potter JD, Ulrich CM2008 Serum leptin concentrations and markers of immune function in overweight or obese postmenopausal women. J Endocrinol 199:51-60
26. Pajvani UB, Du X, Combs TP, Berg AH, Rajala MW, Schulthess T, Engel J, Brownlee M, Scherer PE 2003 Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278:9073-9085
27. Ingelsson E, Larson MG, Yin X, Wang TJ, Meigs JB, Lipinska I, Benjamin EJ, Keaney Jr JF, Vasan RS 2008 Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample. J Clin Endocrinol Metab 93:3149-3157
28. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S 2000 Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 6:1389-1393
29. Kang EH, Moon KC, Lee EY, Lee YJ, Lee EB, Ahn C, Song YW 2009 Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 18:22-28
30. Frol'ová L, Smetana Jr K, Borovská D, Kitanovicová A, Klimesová K, Janatková I, Malícková K, Lukás M, Drastich P, Benes Z, Tucková L, Manning JC, André S, Gabius HJ, Tlaskalová-Hogenová H 2009 Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD? Inflamm Res 58: 503-512
31. Vereecken P, Zouaoui Boudjeltia K, Debray C, Awada A, Legssyer I, Sales F, Petein M, Vanhaeverbeek M, Ghanem G, Heenen M 2006 High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol 31:105-109
32. Rytter E, Vessby B, Asgård R, Johansson C, Sjödin A, Abramsson-Zetterberg L, Möller L, Basu S 2009 Glycaemic status in relation to oxidative stress and inflammation in well-controlled type 2 diabetes subjects. Br J Nutr 101:1423-1426
33. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE 1995 Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333:550-554
34. Schurman L, McCarthy AD, Sedlinsky C, Gangoiti MV, Arnol V, Bruzzone L, Cortizo AM 2008 Metformin reverts deleterious effects of advanced glycation end-products (AGEs) on osteoblastic cells. Exp Clin Endocrinol Diabetes 116:333-340
35. Mercer N, Ahmed H, Etcheverry SB, Vasta GR, Cortizo AM 2007 Regulation of advanced glycation end product (AGE) receptors and apoptosis by AGEs in osteoblast-like cells. Mol Cell Biochem 306: 87-94
36. Hardie DG 2008 Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett 582:81-89
37. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S, Sugiyama T, Miyagishi M, Hara K, Tsunoda M, Murakami K, Ohteki T, Uchida S, Takekawa S, Waki H, Tsuno NH, Shibata Y, Terauchi Y, Froguel P, Tobe K, Koyasu S, Taira K, Kitamura T, Shimizu T, Nagai R, Kadowaki T 2003 Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423: 762-769
38. Yamauchi T, Nio Y, Maki T, Kobayashi M, Takazawa T, Iwabu M, Okada-Iwabu M, Kawamoto S, Kubota N, Kubota T, Ito Y, Kamon J, Tsuchida A, Kumagai K,KozonoH,HadaY, Ogata H,Tokuyama K, Tsunoda M, Ide T, Murakami K, Awazawa M, Takamoto I, Froguel P, Hara K, Tobe K, Nagai R, Ueki K, Kadowaki T 2007 Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med 13:332-339
39. Swarbrick MM, Havel PJ 2008 Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord 6:87-102
40. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Ouchi N, Kihara S, Funahashi T, Matsuzawa Y 2002 Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134-141
41. Schäffler A, Schölmerich J, Büchler C 2005 Mechanisms of disease: adipocytokines and visceral adipose tissue: emerging role in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2:273-280
42. Kim H, Lee J, Hyun JW, Park JW, Joo HG, Shin T 2007 Expression and immunohistochemical localization of galectin-3 in various mouse tissues. Cell Biol Int 31:655-662
43. Lippert E, Gunckel M, Brenmoehl J, Bataille F, Falk W, Scholmerich J, Obermeier F, Rogler G 2008 Regulation of galectin-3 function in mucosal fibroblasts: potential role in mucosal inflammation. Clin Exp Immunol 152:285-297
44. Nishi Y, Sano H, Kawashima T, Okada T, Kuroda T, Kikkawa K, Kawashima S, Tanabe M, Goto T, Matsuzawa Y, Matsumura R, Tomioka H, Liu FT, Shirai K 2007 Role of galectin-3 in human pulmonary fibrosis. Allergol Int 56:57-65